FACILITATE aims to make a model for objective proceedings participant’s information entree and reutilisation for a afloat transparent and ethical ecosystem
Almirall brings its acquisition successful privateness matters and pharmaceutical law, arsenic good arsenic successful the improvement of guidance, standards, and recommendations for returning objective trials information to patients
The task volition past 4 years and involves 27 partners from 16 EU and extra-EU Member States, including diligent associations, hospitals, universities, SMEs, and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
BARCELONA, Spain, November 28, 2022--(BUSINESS WIRE)--Almirall, S.A. (ALM), a planetary biopharmaceutical institution focused connected tegument health, contiguous announced that it is participating successful FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA reutilization for a afloat Transparent and Ethical ecosystem) a patient-driven Innovative Medicines Initiative (IMI) task aimed to create a model for entree and reutilization of objective proceedings subordinate information for a afloat compliant and ethical ecosystem. FACILITATE main nonsubjective is to assistance instrumentality the objective proceedings information to the survey participants, acceptable for reuse successful either further probe oregon successful healthcare practice, improving the existent concern wherever objective information are isolated successful abstracted repositories and cannot beryllium utilized extracurricular the objective trial.
This property merchandise features multimedia. View the afloat merchandise here: https://www.businesswire.com/news/home/20221127005124/en/
Almirall HQ successful Barcelona (Photo: Business Wire)
Almirall's main publication focuses connected providing expertise successful privateness and pharmaceutical instrumentality issues, arsenic good arsenic successful processing guidance, standards, and recommendations for the instrumentality of objective proceedings information to patients. In addition, the institution besides contributes with its expertise successful the specification of objective proceedings usage cases, stakeholder requirements, and the improvement of end-user tools.
Facilitate is based connected a patient-centred, data-driven exertion platform with 27 partners from 17 EU and non-EU Member States. Participants see diligent associations, hospitals, universities, innovative tiny and medium-sized enterprises, and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and with the Università degli Studi di Modena e Reggio Emilia arsenic task coordinator. The project, which was approved by the IMI Joint Undertaking (European Commission and EFPIA) successful 2021, has been launched this twelvemonth unneurotic with the FACILITATE website.
"The motorboat of FACILITATE further advances diligent empowerment successful objective trials. At Almirall, we are excited to lend to this patient-driven IMI task with our coagulated acquisition successful objective trials and our committedness to morals and transparency. This task is afloat aligned with our patient-centricity strategy aimed astatine improving their prime of life," stated Diego Herrera, Almirall’s FACILITATE Project Leader.
"FACILITATE is an IMI-JU task that builds connected the collaborative efforts of galore nationalist and backstage partners and has the intent to negociate the instrumentality of idiosyncratic objective proceedings information successful a trusted ineligible and ethical environment. Leveraging connected a patient's needs, FACILITATE aspiration is to make a prototype process which enables the instrumentality of objective proceedings information during and aft the objective proceedings and allows for the secondary usage of that data", said Prof Johanna Blom, University of Modena-Reggio Emilia (UNIMORE) vice-coordinator of FACILITATE
FACILITATE task has received backing from the Innovative Medicines Initiative 2 Joint Undertaking (JU) nether assistance statement No. 101034366. The JU gets enactment from the European Union’s Horizon 2020 probe and innovation programme and EFPIA.
For much accusation astir FACILITATE, delight sojourn https://facilitate-project.eu/
About Almirall
Almirall is simply a planetary biopharmaceutical institution focused connected tegument health. We collaborate with scientists and healthcare professionals to code patient’s needs done subject to amended their lives. Our Noble Purpose is astatine the halfway of our work: "Transform the patients' satellite by helping them recognize their hopes and dreams for a steadfast life". We put successful differentiated and ground-breaking aesculapian dermatology products to bring our innovative solutions to patients successful need.
The company, founded successful 1943 and headquartered successful Barcelona, is publically traded connected the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a beardown absorption connected the needs of patients. Currently, Almirall has a nonstop beingness successful 21 countries and strategical agreements successful implicit 70, with astir 1,800 employees. Total revenues successful 2021 were 836.5 cardinal euros.
For much information, delight sojourn almirall.com
Legal warning
This papers includes lone summary accusation and is not intended to beryllium exhaustive. The facts, figures and opinions contained successful this document, successful summation to the humanities ones, are "forward-looking statements". These statements are based connected the accusation presently disposable and the champion estimates and assumptions that the Company considers reasonable. These statements impact risks and uncertainties beyond the power of the Company. Therefore, existent results whitethorn disagree materially from those declared by specified forward-looking statements. The Company expressly waives immoderate work to revise oregon update immoderate forward-looking statements, goals oregon estimates contained successful this papers to bespeak immoderate changes successful the assumptions, events oregon circumstances connected which specified forward-looking statements are based, unless required by the applicable law.
View root mentation connected businesswire.com: https://www.businesswire.com/news/home/20221127005124/en/
Contacts
Media interaction Almirall:
Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581
Investors’ Relations interaction
Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087
Corporate Communications contact:
Almirall
Mar Ramírez
mar.ramirez@almirall.com
Phone: (+34) 659614173
English (US)